[1] Katirachi SK, Grønlund MP, Jakobsen KK, et al. The prevalence of HPV in oral cavity squamous cell carcinoma[J]. Viruses, 2023, 15(2): 451.
[2] Pillai J, Chincholkar T, Dixit R, et al. A systematic review of proteomic biomarkers in oral squamous cell cancer[J]. World J Surg Oncol, 2021, 19(1): 315.
[3] 陈美波, 陈清梅, 张彧. 癌抗原 125 中性粒细胞明胶酶相关脂质运载蛋白及人附睾蛋白4在子宫内膜癌患者血清中的表达水平及诊断价值 [J]. 中国妇幼保健, 2022, 37(10): 1881-1883.
[4] 王晓诺, 包香香, 陈芳. 甲壳质酶蛋白 40、糖类抗原 125和人附睾蛋白 4 在子宫内膜癌病人血清中的表达及诊断价值 [J]. 安徽医药, 2021, 25(9): 1766-1770.
[5] Almangush A, Mäkitie AA, Triantafyllou A, et al. Staging and grading of oral squamous cell carcinoma: An update[J]. Oral Oncol, 2020, 107: 104799.
[6] Kato MG, Baek CH, Chaturvedi P, et al. Update on oral and oropharyngeal cancer staging-international perspectives[J]. World J Otorhinolaryngol Head Neck Surg, 2020, 6(1): 66-75.
[7] Stern PL, Dalianis T. Oropharyngeal squamous cell carcinoma treatment in the era of immune checkpoint inhibitors[J]. Viruses, 2021, 13(7): 1234.
[8] Che K, Han WK, Zhang MX, et al. Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma[J]. Oncol Lett, 2021, 21(2): 148.
[9] Crescenzi E, Leonardi A, Pacifico F. NGAL as a potential target in tumor microenvironment[J]. Int J Mol Sci, 2021, 22(22): 12333.
[10] Rahimi S, Roushandeh AM, Ahmadzadeh E, et al. Implication and role of neutrophil gelatinase-associated lipocalin in cancer: Lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types[J]. Mol Biol Rep, 2020, 47(3): 2327-2346.
[11] Schor AM, Woolston AM, Kankova K, et al. MigrationStimulating factor (MSF): Its role in the tumour microenvironment[J]. Adv Exp Med Biol, 2021, 1329: 351-397.
[12] Caldeira PC, Vieira ÉLM, Sousa AA, et al. Immunophenotype of neutrophils in oral squamous cell carcinoma patients[J]. J Oral Pathol Med, 2017, 46(9): 703-709.
[13] Hiromoto T, Noguchi K, Yamamura M, et al. Up-regulation of neutrophil gelatinase-associated lipocalin in oral squamous cell carcinoma: Relation to cell differentiation[J]. Oncol Rep, 2011, 26(6): 1415-1421.
[14] Rusak A, Jabłońska K, Dzięgiel P. The role of YKL-40 in a cancerous process[J]. Postepy Hig Med Dosw (Online), 2016, 70(0): 1286-1299.
[15] Zhao T, Su ZP, Li YC, et al. Chitinase-3 like-protein-1 function and its role in diseases[J]. Signal Transduct Target Ther, 2020, 5(1): 201.
[16] Pouyafar A, Heydarabad MZ, Mahboob S, et al. Angiogenic potential of YKL-40 in the dynamics of tumor niche[J]. Biomedecine Pharmacother, 2018, 100: 478-485.
[17] Roslind A, Johansen JS, Christensen IJ, et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival[J]. Int J Cancer, 2008, 122(4): 857-863.
[18] Suwanwela J, Osathanon T. Inflammation related genes are upregulated in surgical margins of advanced stage oral squamous cell carcinoma[J]. J Oral Biol Craniofac Res, 2017, 7(3): 193-197.
|